BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25527510)

  • 21. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.
    Kelly LM; Barila G; Liu P; Evdokimova VN; Trivedi S; Panebianco F; Gandhi M; Carty SE; Hodak SP; Luo J; Dacic S; Yu YP; Nikiforova MN; Ferris RL; Altschuler DL; Nikiforov YE
    Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4233-8. PubMed ID: 24613930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract.
    Fuehrer NE; Keeney GL; Ketterling RP; Knudson RA; Bell DA
    Arch Pathol Lab Med; 2012 Jun; 136(6):623-6. PubMed ID: 22646268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.
    Yi ES; Boland JM; Maleszewski JJ; Roden AC; Oliveira AM; Aubry MC; Erickson-Johnson MR; Caron BL; Li Y; Tang H; Stoddard S; Wampfler J; Kulig K; Yang P
    J Thorac Oncol; 2011 Mar; 6(3):459-65. PubMed ID: 21278610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterations.
    Choi E; Williamson SR; Montironi R; Zhang S; Wang M; Eble JN; Grignon DJ; Lopez-Beltran A; Idrees MT; Baldridge LA; Scarpelli M; Jones CL; Wang L; MacLennan GT; Osunkoya AO; Cheng L
    Histopathology; 2015 Jul; 67(1):20-38. PubMed ID: 25406945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.
    Minca EC; Lanigan CP; Reynolds JP; Wang Z; Ma PC; Cicenia J; Almeida FA; Pennell NA; Tubbs RR
    J Thorac Oncol; 2014 Apr; 9(4):464-8. PubMed ID: 24736067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria.
    von Laffert M; Warth A; Penzel R; Schirmacher P; Kerr KM; Elmberger G; Schildhaus HU; Büttner R; Lopez-Rios F; Reu S; Kirchner T; Pauwels P; Specht K; Drecoll E; Höfler H; Aust D; Baretton G; Bubendorf L; Stallmann S; Fisseler-Eckhoff A; Soltermann A; Tischler V; Moch H; Penault-Llorca F; Hager H; Schäper F; Lenze D; Hummel M; Dietel M
    J Thorac Oncol; 2014 Nov; 9(11):1685-92. PubMed ID: 25436802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing.
    Selinger C; Cooper W; Lum T; McNeil C; Morey A; Waring P; Amanuel B; Millward M; Peverall J; Van Vliet C; Christie M; Tran Y; Diakos C; Pavlakis N; Gill AJ; O'Toole S
    Histopathology; 2015 Nov; 67(5):654-63. PubMed ID: 25847523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
    Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
    Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
    Lira ME; Kim TM; Huang D; Deng S; Koh Y; Jang B; Go H; Lee SH; Chung DH; Kim WH; Schoenmakers EF; Choi YL; Park K; Ahn JS; Sun JM; Ahn MJ; Kim DW; Mao M
    J Mol Diagn; 2013 Jan; 15(1):51-61. PubMed ID: 23246132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.
    Koh Y; Kim DW; Kim TM; Lee SH; Jeon YK; Chung DH; Kim YW; Heo DS; Kim WH; Bang YJ
    J Thorac Oncol; 2011 May; 6(5):905-12. PubMed ID: 21358343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of ALK expression in different human cancer types.
    Tennstedt P; Strobel G; Bölch C; Grob T; Minner S; Masser S; Simon R
    J Clin Pathol; 2014 Jun; 67(6):477-81. PubMed ID: 24478382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
    Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
    Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients.
    Tuononen K; Kero M; Mäki-Nevala S; Sarhadi VK; Tikkanen M; Wirtanen T; Rönty M; Knuuttila A; Knuutila S
    Genes Chromosomes Cancer; 2014 Nov; 53(11):895-901. PubMed ID: 24942490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH.
    Hutarew G; Hauser-Kronberger C; Strasser F; Llenos IC; Dietze O
    Histopathology; 2014 Sep; 65(3):398-407. PubMed ID: 24612196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.
    Savic S; Diebold J; Zimmermann AK; Jochum W; Baschiera B; Grieshaber S; Tornillo L; Bisig B; Kerr K; Bubendorf L
    Lung Cancer; 2015 Aug; 89(2):104-9. PubMed ID: 26056079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements--comparison of multiple immunohistochemical methods.
    Zwaenepoel K; Van Dongen A; Lambin S; Weyn C; Pauwels P
    Histopathology; 2014 Oct; 65(4):539-48. PubMed ID: 24621075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rare ALK expression but no ALK rearrangement in pancreatic ductal adenocarcinoma and neuroendocrine tumors.
    Graham RP; Oliveira AM; Zhang L
    Pancreas; 2013 Aug; 42(6):949-51. PubMed ID: 23851431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
    Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
    Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.